Last reviewed · How we verify
Guanidin (GUANIDINE)
At a glance
| Generic name | GUANIDINE |
|---|---|
| Sponsor | Merck & Co. |
| Drug class | Acetylcholine Releasing Agent |
| Target | Voltage-gated potassium channel |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1939 |
Approved indications
- Eaton-Lambert syndrome
Common side effects
Key clinical trials
- Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants (PHASE1)
- Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion (PHASE2)
- Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib (PHASE1)
- Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2)
- Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function (PHASE2)
- Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) (PHASE2)
- Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients (PHASE4)
- PMPR and Chlorhexidine on Periodontal Disease and Vascular Function (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Guanidin CI brief — competitive landscape report
- Guanidin updates RSS · CI watch RSS
- Merck & Co. portfolio CI